This article is for informational and educational purposes only. Nothing here constitutes medical advice. Always disclose all supplements and peptides to your healthcare provider before starting, stopping, or changing any medication.
Why Peptide-Drug Interactions Matter
Peptides are biologically active compounds that interact with receptors, enzymes, and signaling pathways throughout the body. When combined with prescription medications — which target many of the same systems — the potential for clinically significant interactions is real. Yet most healthcare providers receive little training on research peptides, and most peptide users do not disclose their use to their doctors.
This disconnect creates risk. The interactions below are the ones most likely to cause harm, and understanding them is essential for anyone using peptides alongside conventional medications. This guide is intended to help you have informed conversations with your healthcare provider — not to replace those conversations.
GLP-1 Agonists and Oral Medications
GLP-1 receptor agonists — including semaglutide, tirzepatide, and research peptides that target this pathway — significantly slow gastric emptying. This is part of how they reduce appetite and improve glucose control, but it has a direct pharmacological consequence: any medication taken orally may be absorbed more slowly and unpredictably.
Medications most affected include:
- Oral contraceptives: Delayed absorption may reduce peak concentrations, potentially compromising efficacy. Clinicians may recommend barrier methods during the initial dose-escalation period.
- Levothyroxine: Already sensitive to absorption timing. GLP-1-induced gastroparesis can alter TSH levels, requiring more frequent thyroid monitoring.
- Narrow therapeutic index drugs: Warfarin, lithium, certain anti-seizure medications, and digoxin all require predictable absorption. Changes in gastric transit time can push levels outside the therapeutic window.
- Oral antibiotics: Delayed absorption may reduce peak concentrations needed for bactericidal activity.
Clinical action: If you are using any GLP-1 agonist, ensure your prescribing physician knows. Medication timing adjustments, increased blood level monitoring, or route-of-administration changes may be necessary.
GLP-1 Agonists and Anesthesia
The American Society of Anesthesiologists (ASA) issued guidance in 2023 regarding GLP-1 receptor agonists and surgical procedures. Because these drugs delay gastric emptying, patients may retain stomach contents longer than expected — increasing aspiration risk during sedation and general anesthesia.
The ASA recommends that patients on weekly GLP-1 agonists hold their dose for at least one week before elective procedures requiring anesthesia. For daily formulations, the recommendation is to hold for at least 24 hours. Some anesthesiologists recommend a longer washout period or pre-operative gastric ultrasound to assess residual stomach volume.
Clinical action: Always inform your anesthesiologist about GLP-1 agonist use, including research peptides. This applies to any procedure involving sedation, including dental work and endoscopy.
GH Secretagogues and Insulin/Diabetes Medications
Growth hormone secretagogues — including MK-677 (ipamorelin), CJC-1295, tesamorelin, and sermorelin — raise growth hormone and, consequently, IGF-1 levels. Growth hormone is a counter-regulatory hormone to insulin: it opposes insulin's action and can reduce insulin sensitivity.
For individuals on insulin, metformin, sulfonylureas, or other glucose-lowering medications, GH secretagogues may:
- Increase fasting blood glucose levels
- Worsen HbA1c over time
- Require dose adjustments to diabetes medications
- Increase the risk of hyperglycemia, particularly with MK-677 (which has notable insulin resistance effects in some individuals)
Clinical action: If you have diabetes or prediabetes and are considering a GH secretagogue, inform your endocrinologist. More frequent glucose monitoring (CGM if possible) during the first 4-8 weeks is advisable.
GH Secretagogues and Thyroid Medications
Growth hormone influences thyroid hormone metabolism by increasing the peripheral conversion of T4 (thyroxine) to T3 (triiodothyronine). In individuals on levothyroxine replacement therapy, introducing a GH secretagogue can accelerate T4-to-T3 conversion, potentially leading to:
- Decreased free T4 levels (as more is converted to T3)
- Symptoms of relative T4 deficiency despite adequate dosing
- Altered TSH readings that may confuse standard thyroid monitoring
Clinical action: Recheck thyroid panels (including free T3, free T4, and TSH) 6-8 weeks after starting any GH secretagogue. Dose adjustments to levothyroxine may be needed.
9-Me-BC and SSRIs: Serotonin Syndrome Risk
9-Methyl-β-carboline (9-Me-BC) is a research compound investigated for its neuroprotective and cognitive-enhancing properties. One of its mechanisms involves inhibition of monoamine oxidase (MAO) enzymes — the same enzymes targeted by MAOI antidepressants.
Combining any MAO inhibitor with serotonergic medications creates a risk of serotonin syndrome, a potentially life-threatening condition characterized by:
- Agitation, confusion, rapid heart rate
- Elevated body temperature, sweating
- Muscle rigidity, tremor, diarrhea
- In severe cases: seizures, organ failure, death
Medications that should NOT be combined with 9-Me-BC include SSRIs (fluoxetine, sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclic antidepressants, tramadol, triptans (migraine medications), dextromethorphan, and St. John's Wort.
Clinical action: This is one of the most dangerous peptide-drug interactions. If you are on any serotonergic medication, 9-Me-BC should be avoided entirely unless under direct medical supervision with appropriate washout periods.
Selank, DSIP, and Sedating Medications
Selank (an anxiolytic peptide) and DSIP (delta sleep-inducing peptide) both modulate GABAergic and other inhibitory neurotransmitter systems. When combined with benzodiazepines (alprazolam, diazepam, clonazepam), Z-drugs (zolpidem, zopiclone), barbiturates, or other CNS depressants, there is a risk of additive sedation.
This can manifest as:
- Excessive drowsiness and impaired coordination
- Respiratory depression (particularly with opioids or high-dose benzodiazepines)
- Cognitive impairment and memory problems
- Increased fall risk, especially in older individuals
Clinical action: Inform your prescriber if you are using Selank or DSIP alongside any sedating medication. Alcohol also compounds this risk and should be used cautiously.
LL-37 and Immunosuppressants
LL-37 is an antimicrobial peptide that modulates innate immune function — it enhances immune cell recruitment, promotes inflammation in response to pathogens, and influences adaptive immunity. For individuals on immunosuppressive therapy (organ transplant recipients, autoimmune disease patients on biologics, those taking corticosteroids, methotrexate, or calcineurin inhibitors), LL-37 may work in opposition to the immunosuppressive regimen.
The theoretical risks include undermining graft tolerance in transplant patients, triggering autoimmune flares, or interfering with the mechanism of biologic medications. While direct clinical data on this interaction is limited, the mechanistic concern is well-grounded.
Clinical action: LL-37 should be avoided by anyone on immunosuppressive therapy without explicit clearance from their immunologist or transplant team.
NAD+ and Chemotherapy
NAD+ (nicotinamide adenine dinucleotide) supplementation — whether by IV infusion, subcutaneous injection, or oral precursors like NMN and NR — supports cellular energy metabolism and DNA repair through sirtuin and PARP activation. In healthy cells, this is generally beneficial. However, cancer cells also rely on NAD+ for survival, proliferation, and resistance to treatment.
Preclinical research suggests that elevated NAD+ levels may protect tumor cells from the DNA damage inflicted by chemotherapy and radiation, potentially reducing treatment efficacy. This is an active area of research with conflicting findings, but the precautionary principle applies strongly here.
Clinical action: Anyone undergoing cancer treatment should avoid NAD+ supplementation unless their oncologist specifically approves it. This includes oral NMN and NR supplements, not just injectable NAD+.
The Universal Rule: Full Disclosure
The single most important thing you can do to manage peptide-drug interaction risk is to tell your healthcare provider about everything you are taking — every peptide, every supplement, every research compound. Many people hesitate to disclose peptide use because they worry about judgment or legal concerns. However, your physician needs a complete picture to keep you safe.
If your current provider is not receptive to discussing peptides, consider seeking one who specializes in integrative or functional medicine. The risk of an undisclosed interaction far outweighs the discomfort of a candid conversation.
For individual peptide safety profiles, explore our peptide database. For more on safe peptide use, see our beginner's guide.